Literature DB >> 16867695

Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.

M Polgár1, L Vereczkey, I Nyáry.   

Abstract

The pharmacokinetics of vinpocetine (ethyl apovincaminate, Cavinton) and its metabolite, apovincaminic acid, was studied in patients with cerebrovascular disorders. Vinpocetine (1 mg/kg) was infused intravenously over 25 min. The elimination half-life of the parent drug in plasma was 4.7+/-2.13 h. Total clearance of vinpocetine was 0.79+/-0.1 1 h(-1) kg(-1). The presence of vinpocetine in cerebrospinal fluid shows that the drug is able to pass through the blood-brain barrier and reach the central nervous system which is a possible site of action. The maximum increase of cerebral blood flow (25%) was measured at 32 min after the start of the infusion.

Entities:  

Year:  1985        PMID: 16867695     DOI: 10.1016/0731-7085(85)80016-9

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells.

Authors:  Ruozhou Tom Liu; Aikun Wang; Eleanor To; Jiangyuan Gao; Sijia Cao; Jing Z Cui; Joanne A Matsubara
Journal:  Exp Eye Res       Date:  2014-07-17       Impact factor: 3.467

2.  Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans.

Authors:  P Miskolczi; K Kozma; M Polgár; L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

Review 3.  Pharmacokinetics and metabolism of vincamine and related compounds.

Authors:  L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

4.  Study on the absorption of vinpocetine and apovincaminic acid.

Authors:  P Pudleiner; L Vereczkey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441

5.  Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

Authors:  G Storm; B Oosterhuis; F A Sollie; H W Visscher; W Sommer; H Beitinger; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

6.  Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.

Authors:  P Miskolczi; L Vereczkey; L Szalay; C Göndöc
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Vinpocetine Ameliorates Acetic Acid-Induced Colitis by Inhibiting NF-κB Activation in Mice.

Authors:  Bárbara B Colombo; Victor Fattori; Carla F S Guazelli; Tiago H Zaninelli; Thacyana T Carvalho; Camila R Ferraz; Allan J C Bussmann; Kenji W Ruiz-Miyazawa; Marcela M Baracat; Rúbia Casagrande; Waldiceu A Verri
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

8.  Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury.

Authors:  Ke Wang; Li Wen; Wenhui Peng; Hailing Li; Jianhui Zhuang; Yuyan Lu; Baoxin Liu; Xiankai Li; Weiming Li; Yawei Xu
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

9.  Updates of Recent Vinpocetine Research in Treating Cardiovascular Diseases.

Authors:  Chongyang Zhang; Chen Yan
Journal:  J Cell Immunol       Date:  2020
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.